海尔生物(688139) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was CNY 558.74 million, a year-on-year increase of 0.51%, and a quarter-on-quarter increase of 4.17%[3] - Net profit attributable to shareholders for Q3 2024 was CNY 74.80 million, a decrease of 5.00% compared to the same period last year[1] - Total operating revenue for the first three quarters of 2024 was approximately ¥1.78 billion, a decrease of 2.4% compared to ¥1.83 billion in the same period of 2023[19] - Net profit for the first three quarters of 2024 was approximately ¥319 million, a decline of 12.7% from ¥366 million in the same period of 2023[20] - The total comprehensive income for the first three quarters of 2024 was approximately ¥295 million, down from ¥335 million in the same period of 2023[21] Research and Development - The total R&D investment for Q3 2024 was CNY 80.13 million, accounting for 14.34% of revenue, a decrease of 0.96 percentage points year-on-year[2] - Research and development expenses for the first three quarters of 2024 were approximately ¥224 million, down 7.9% from ¥243 million in the same period of 2023[19] Market Performance - Revenue from the domestic market for the first three quarters was CNY 1.25 billion, a year-on-year increase of 2.97%[4] - Revenue from the overseas market for the first three quarters was CNY 527 million, a year-on-year decrease of 13.32%[4] - The life sciences segment achieved revenue of CNY 863 million in the first three quarters, a year-on-year increase of 3.36%[4] Cash Flow and Investments - The company reported a net cash flow from operating activities of CNY 113.97 million for the year-to-date, a decrease of 31.96% year-on-year[1] - Cash inflow from operating activities was approximately ¥1.65 billion, a decrease of 8.8% compared to ¥1.82 billion in the first three quarters of 2023[22] - The total cash inflow from investment activities was ¥2,056,540,467.27, down from ¥4,714,330,619.04 in the previous year, indicating a decrease of about 56%[23] - The net cash flow from investment activities was -¥454,558,740.26, contrasting with a positive cash flow of ¥352,969,899.03 in Q3 2023[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,200[11] - The largest shareholder, Qingdao Haier Biomedical Holdings Co., Ltd., holds 100,591,463 shares, accounting for 31.64% of total shares[12] - The second-largest shareholder, Qingdao Haizhi Huiying Equity Investment Management Co., Ltd., holds 32,103,659 shares, representing 10.10%[12] Assets and Liabilities - As of September 30, 2024, total assets reached CNY 5,641,694,736.82, an increase from CNY 5,525,682,568.67 at the end of 2023, reflecting a growth of approximately 2.1%[18] - Current assets totaled CNY 2,660,812,428.80, up from CNY 2,536,028,043.52, indicating an increase of about 4.9%[16] - The total liabilities amounted to CNY 1,100,219,008.24, compared to CNY 1,085,719,569.95, reflecting a slight increase of around 1.3%[17] - The company's equity attributable to shareholders increased to CNY 4,301,632,773.15 from CNY 4,230,710,929.50, representing a growth of approximately 1.7%[17] Financial Costs and Income - The company reported a financial expense of approximately -¥33.90 million, compared to -¥14.89 million in the same period of 2023, indicating an increase in financial costs[19] - Investment income for the first three quarters of 2024 was approximately ¥16.61 million, a significant decrease of 77.4% compared to ¥73.35 million in the same period of 2023[19] Tax and Subsidies - The company will benefit from a VAT deduction of 3,441,593.41 RMB, which will have a continuous impact on profits for the next five years[9] - Government subsidies related to assets, amounting to 2,360,999.75 RMB, will also have a sustained impact on the company's profits[9]